Results 91 to 100 of about 4,308 (211)

Total protein, albumin and low-molecular-weight protein excretion in HIV-positive patients

BMC Nephrology, 2012
Background Chronic kidney disease is common in HIV positive patients and renal tubular dysfunction has been reported in those receiving combination antiretroviral therapy (cART).
Campbell Lucy J, Dew Tracy, Salota Rashim, Cheserem Emily, Hamzah Lisa, Ibrahim Fowzia, Sarafidis Pantelis A, Moniz Caje F, Hendry Bruce M, Poulton Mary, Sherwood Roy A, Post Frank A   +11 more
doaj   +1 more source

Production of a buttermilk fraction with high antioxidant activity using enzymatic hydrolysis and ultrafiltration in a membrane bioreactor

International Journal of Dairy Technology, Volume 79, Issue 2, April–June 2026.
Sequential enzymatic hydrolysis and ultrafiltration of buttermilk significantly increased antioxidant activity, effectively valorising this dairy by‐product into a functional ingredient. Background, Context, or Rationale Buttermilk, a by‐product of butter production, contains proteins with encrypted bioactive peptides that may display antioxidant ...
Sandrini Slongo Fortuna, Samarah Graciola, Fabiano Vieira Trindade, Gustavo Henrique Tozatti, Dominique Trindade Novello, Juliana Steffens, Ilizandra Aparecida Fernandes, Vandré Barbosa Brião   +7 more
wiley   +1 more source

TFV combined with NP-EFV or NP-SQV showed strong synergism.

, 2013
Combination effects of free tenofovir (TFV) with efavirenz (EFV) or saquinavir (SQV) were quantified using the TZM-bl infectivity assay and the HIV-1 BaL isolate. The combination index (CI) was determined as described by Chou and Talalay.
Emily Krogstad (116925), Thanyanan Chaowanachan (116931), Kim A. Woodrow (116937), Cameron Ball (116922)   +3 more
core   +1 more source

Development and Validation of an Immunoassay for Tenofovir in Urine as a Real-Time Metric of Antiretroviral Adherence

EClinicalMedicine, 2018
Background: Pharmacologic adherence measures were critical to the interpretation of the tenofovir (TFV)-disoproxil-fumarate/emtricitabine (TDF/FTC) PrEP trials.
Monica Gandhi, Peter Bacchetti, Warren C. Rodrigues, Matthew Spinelli, Catherine A. Koss, Paul K. Drain, Jared M. Baeten, Nelly R. Mugo, Kenneth Ngure, Leslie Z. Benet, Hideaki Okochi, Guohong Wang, Michael Vincent   +12 more
doaj   +1 more source

There is vaginal penetration of TFV from both oral and topical rectal exposures.

, 2014
(A) Vaginal fluid detection of both TFV and TFVdp concentration in vaginal fluid is higher following rectal dosing than following single oral dosing TFVdp.
Kuo-Hsiung Yang (650738), Craig Hendrix (650739), Ross Cranston (650741), Karen Tanner (203383), Christine Mauck (203420), Namandje Bumpus (650740), Julie Elliott (203365), Angela D. M. Kashuba (200181), Nicola Richardson-Harman (650630), Peter A. Anton (203359), Ian McGowan (203424)   +10 more
core   +1 more source

Effect of Liraglutide on Intermittent Hypoxia‐Induced Metabolic Dysfunction: From Bench to Bedside

Journal of Sleep Research, Volume 35, Issue 2, April 2026.
ABSTRACT Intermittent hypoxia (IH)‐mediated adipose tissue inflammation with M1 macrophage polarisation plays a key role in the pathogenesis of metabolic diseases in obstructive sleep apnoea (OSA). Effective treatment strategies are so far lacking.
Cliona O'Donnell, Ailbhe King, Guillaume Vial, Emily O'Neill, Shane Crilly, Jonathan D. Dodd, David J. Murphy, Elise Belaidi, Jean‐Louis Pepin, Claire Arnaud, Donal O'Shea, Silke Ryan   +11 more
wiley   +1 more source

TFV (A) and TFVdp (B) concentrations in rectal tissue homogenate are predicted by Rectal Sponge TFV.

, 2014
...
Kuo-Hsiung Yang (650738), Craig Hendrix (650739), Ross Cranston (650741), Karen Tanner (203383), Christine Mauck (203420), Namandje Bumpus (650740), Julie Elliott (203365), Angela D. M. Kashuba (200181), Nicola Richardson-Harman (650630), Peter A. Anton (203359), Ian McGowan (203424)   +10 more
core   +1 more source

Compartment TFV and TFVdp efficacy concentrations (EC_50,90,95) predicted by logistic regression to suppress HIV infection following single oral TDF, single topical TFV 1% gel and 7-day topical TFV 1% gel in vivo product use.

, 2014
§Predicted compartment dose concentrations to suppress 50, 90 and 95% of HIV infection interpolated from the logistic regression probability curve where infection was defined as cumulative p24 pg/mL ≥500.Actual drug concentrations in the delivered ...
Angela Kashuba (376992), Karen Tanner (203383), Christine Mauck (203420), Namandjé N. Bumpus (5089418), Julie Elliott (203365), Nicola Richardson-Harman (650630), Ross D. Cranston (397979), Peter A. Anton (203359), Kuo Yang (280921), Craig W. Hendrix (232212), Ian McGowan (203424)   +10 more
core   +1 more source

Pharmacokinetics of TFV for different doses of oral TDF at plateau and intracellular TFV-DP concentrations after treatment cessation.

, 2012
A: Predicted pharmacokinetics of TFV after once daily 75-, 150-, 300- and 600 mg oral TDF (lines) together with data from [7], [9], [12] (markers). B: Goodness-of-fit plot for the plasma pharmacokinetics of TFV with data from 3 clinical studies and 4 ...
Sulav Duwal (152805), Christof Schütte (151327), Max von Kleist (152808)   +2 more
core   +1 more source

Naturally occurring genetic variants of AK2 and the resulting impact on TFV phosphorylation.

, 2018
Wild-type (WT) AK2 and variants were expressed in and purified from E. coli in order to evaluate their effects on TFV phosphorylation in vitro. Proteins were incubated with 1 mM TFV in assay buffer for 2.5 h before reaction was quenched.
Estelle Piwowar-Manning (433133), Frits van Griensven (203531), Timothy H. Holtz (139443), Joseph Tillotson (1420354), Sharon Mannheimer (438426), Dominique B. Figueroa (5089424), Robert M. Grant (128215), Linda-Gail Bekker (60754), Kevin Bokoch (5089421), James P. Hughes (205509), Maoji Li (5089427), Namandjé N. Bumpus (5089418), Craig W. Hendrix (232212)   +12 more
core   +1 more source